Clinical trials: Ovarian, Fallopian, and Primary Peritoneal Cancer
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
In April 2017, Tesaro, Inc. opened an expanded access program (EAP) to make niraparib, an investigational poly (ADP-ribose) polymerase (PARP) inhibitor, available to eligible women with recurrent epithelial ovarian, fallopian…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04546373
- Testing
- Niraparib
- Where
- 57 sites in Spain
- Volunteers
- 316 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
Ovarian Epithelial Cancer Recurrent, Fallopian Tube Carcinoma
Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
The purpose of this study is to evaluate the role of secondary cytoreduction (SCR) and validate the risk model of patient selection criteria in platinum-sensitive recurrent ovarian cancer.
- Conditions
- Ovarian Epithelial Cancer Recurrent, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT01611766
- Testing
- Secondary Cytoreductive Surgery, Salvage Chemotherapy
- Where
- 4 sites in China
- Volunteers
- 356 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Ovarian Cancer, Fallopian Tube Cancer
Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
The purpose of this study is to evaluate giving chemotherapy drugs directly into the abdomen (belly) along with intravenous administration.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer
- Trial name
- NCT00582205
- Testing
- Paclitaxel, Cisplatin IP
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Oklahoma
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
This phase I trial investigates the side effects and best dose of abexinostat and palbociclib when given together with fulvestrant in treating patients with breast or gynecologic cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT04498520
- Testing
- Abexinostat Tosylate, Fulvestrant, Palbociclib
- Sponsor
- Pamela Munster
Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma
A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care
This is a randomized, double-blind, placebo-controlled,parallel-group preliminary verifying study about safety and efficacy of maintenance DCVAC/OvCa after first-line chemotherapy added to standard of care in patients with newly…
- Conditions
- Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT04834544
- Testing
- DCVAC/OvCa
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Peking University Third Hospital
Endometrial Carcinoma, Stage 0 Fallopian Tube Cancer AJCC v7
Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer
This pilot clinical trial studies how well web-based coping and communication skills intervention works in improving psychological adaptation in patients with gynecological cancer.
- Conditions
- Endometrial Carcinoma, Stage 0 Fallopian Tube Cancer AJCC v7, Stage I Fallopian Tube Cancer AJCC v6 and v7, Stage I Ovarian Cancer AJCC v6 and v7
- Trial name
- NCT03902379
- Testing
- Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer Female, Breast Neoplasm
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
The purpose of this study is to invite all people diagnosed with cancer who meet the eligibility criteria to complete questionnaires before their treatment begins and at regular intervals over time to assess the impact of cancer…
- Conditions
- Breast Cancer Female, Breast Neoplasm, Non-Hodgkin's B-cell Lymphoma, Non-Hodgkin's Lymphoma, Adult High Grade
- Trial name
- NCT03000192
- Where
- 111 sites in United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int
This is a Phase I trial to determine the maximum tolerated dose/maximum feasible dose (MTD/MFD) of a single infusion of FATE-NK100 via intra-peritoneal catheter in women with recurrent ovarian, fallopian tube or primary…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03213964
- Testing
- FATE-NK100, Interleukin-2
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Epithelial Ovarian Cancer, Primary Peritoneal Cancer
Neoadjuvant Therapy for Ovarian Cancer
This study is to determine the feasibility of administering neoadjuvant carboplatin, paclitaxel, and bevacizumab without excessive dose modification or cycle delay in patients with epithelial ovarian cancer, primary peritoneal…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT01146795
- Testing
- Carboplatin, Paclitaxel, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Jason D. Wright
Breast Cancer, Ovarian Cancer
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
In this study, the researchers want to learn more about Vigil and durvalumab in advanced women's cancers: 1) how much of Vigil in combination with durvalumab (MEDI4736) can be given with an acceptable level of side effects, 2)…
- Conditions
- Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT02725489
- Testing
- Vigil, Durvalumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mary Crowley Medical Research Center
Primary Peritoneal Carcinoma, Ovarian Carcinoma
Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
This is a prospective study to evaluate the hypothesis that platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy is associated with improved maximal surgical…
- Conditions
- Primary Peritoneal Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma
- Trial name
- NCT01519869
- Testing
- neoadjuvant chemotherapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Rachel Miller
Ovarian Neoplasm, Fallopian Tube Cancer
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
Background: Sorafenib and bevacizumab are anti-cancer drugs that work by targeting the blood vessels that allow tumors to grow. Using the two drugs together may more effectively block the formation of blood vessels that feed…
- Conditions
- Ovarian Neoplasm, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00436215
- Testing
- Bevacizumab, BAY 43-9006
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
This pilot, phase II trial studies how well everolimus and letrozole work in treating patients with hormone receptor positive ovarian, fallopian tube, or primary peritoneal cavity cancer that has come back.
- Conditions
- Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma
- Trial name
- NCT02283658
- Testing
- Everolimus, Laboratory Biomarker Analysis, Letrozole
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Ovarian Epithelial Cancer Recurrent, Fallopian Tube Cancer
PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer
Efficacy of PankoMab-GEX vs Placebo in maintaining a response to chemotherapy in advanced ovarian, fallopian tube or primary peritoneal cancer.
- Conditions
- Ovarian Epithelial Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01899599
- Testing
- PankoMab-GEX
- Where
- 50 sites in Germany, Hungary and 6 more
- Volunteers
- 216 people
- Sponsor
- Glycotope GmbH
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- FORWARD I (NCT02631876)
- Testing
- Mirvetuximab soravtansine, Paclitaxel, Pegylated liposomal doxorubicin
- Where
- 131 sites in United States, Belgium and 11 more
- Volunteers
- 366 people
- Sponsor
- ImmunoGen, Inc.
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
This randomized phase II trial studies the side effects and how well giving paclitaxel with or without viral therapy works in treating patients with ovarian epithelial, fallopian tube, or primary peritoneal cancer that has come…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01199263
- Testing
- Laboratory Biomarker Analysis, Paclitaxel, Pelareorep
- Where
- 36 sites in United States
- Volunteers
- 108 people
- Sponsor
- National Cancer Institute (NCI)
Breast Carcinoma, Fallopian Tube Carcinoma
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer
This clinical trial is studying the incidence of cancer in women at increased genetic risk of ovarian cancer. Gathering information about genetic factors in women with an increased risk of ovarian cancer over time may help…
- Conditions
- Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Neoplasm, Primary Peritoneal Carcinoma
- Trial name
- NCT01139957
- Testing
- Evaluation of Cancer Risk Factors, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 141 sites in United States
- Volunteers
- 1,916 people
- Sponsor
- Gynecologic Oncology Group
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)
The purpose of this study is to answer the fundamental question 'The Optimal Timing of Surgery' in advanced ovarian cancer patients with different tumor burden, and to perform translational study.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT04515602
- Testing
- Primary debulking surgery, Neoadjuvant chemotherapy, PARPi
- Where
- 4 sites in China
- Volunteers
- 410 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Ovarian Cancer, Primary Peritoneal Cancer
Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
The purpose of this study is to test the safety of the drug olaparib at different dose levels. It will be given with the standard initial chemotherapy for cancer as well as a drug called bevacizumab.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT02121990
- Testing
- Paclitaxel,, Bevacizumab, Cisplatin
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7
Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
This phase I trial studies the side effects and best dose of veliparib when given together with floxuridine in treating patients with epithelial ovarian, primary peritoneal cavity, or fallopian tube cancer that has spread to…
- Conditions
- Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
- Trial name
- NCT01749397
- Testing
- Floxuridine, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)